FROVATRIPTAN SUCCINATE (frovatriptan succinate) by Leadingtac Pharmaceutical is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache, migraine. First approved in 2018.
Drug data last refreshed 20h ago
5-HT 1B/1D receptors. The therapeutic activity of frovatriptan succinate is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel…
Worked on FROVATRIPTAN SUCCINATE at Leadingtac Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.